Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weakness and include autoimmune, toxic, and genetic conditions. Adults with NMJ disorders are most often antibody mediated, with MG being the most common, having a prevalence of approximately 1 in 10,000, and with women being affected about twice as often as men. This article focuses on advances in management of autoimmune MG and LEMS.
['Bodkin|Cynthia|C|', 'Pascuzzi|Robert M|RM|']
D000328:Adult D005260:Female D006801:Humans D015624:Lambert-Eaton Myasthenic Syndrome D008297:Male D009157:Myasthenia Gravis
Myasthenia gravis Weakness Complement inhibitor Lambert Eaton myasthenic syndrome Thymectomy